"PRE-IDE" SUBMISSIONS BEING ACCEPTED BY FDA TO IMPROVE PROGRAM EFFICIENCY; GREATER USE OF FEASIBILITY STUDIES IN CLINICAL PROTOCOLS ALSO ENCOURAGED
This article was originally published in The Gray Sheet
Executive Summary
FDA's device center is accepting "pre-original" investigational device exemption submissions from manufacturers in an effort to improve the IDE approval rate during the first review cycle, agency staffers say.